Clinical Scorecard: Identifying Biomarkers for Enhanced Risk Prediction in Women

At a Glance

Key Highlights

• Women remain underdiagnosed and undertreated for ASCVD despite higher lifetime risk after menopause due to loss of endogenous estrogen.
• Sex-specific lipid biomarkers show differential predictive value: remnant cholesterol predicts events in both sexes; ApoA-1 and TG/HDL-C ratio predict only in women; ceramide-based scores predict only in men.
• LDL-C may have limited prognostic value in elderly, high-risk, statin-treated populations; alternative markers like ApoB, non-HDL-C, and residual-risk biomarkers are important in women.

Guideline-Based Recommendations

Diagnosis

• Incorporate female-specific risk enhancers such as early menopause, eclampsia, and hypertensive pregnancy disorders in risk assessment.
• Use ApoB or non-HDL-C as primary lipid targets alongside LDL-C for more accurate risk prediction in women.
• Consider measuring Lp(a) especially postmenopause due to its genetic risk contribution.

Management

• Target lipid management beyond LDL-C, addressing residual risk with therapies modulating remnant cholesterol and HDL-related indices.
• Recognize the influence of therapies (statins, hormone replacement therapy, omega-3 fatty acids) on lipid biomarkers and ceramide metabolism.
• Tailor treatment strategies considering sex-specific biology and biomarker profiles.

Monitoring & Follow-up

• Monitor lipid parameters including ApoB, non-HDL-C, remnant cholesterol, and ApoA-1 for comprehensive risk evaluation.
• Be cautious interpreting ceramide-based scores in women due to potential calibration bias and therapy effects.
• Assess changes in lipid biomarkers in context of menopausal status, comorbidities, and treatment adherence.

Risks

• Underdiagnosis and undertreatment of women due to reliance on male-validated biomarkers and algorithms.
• Potential misclassification of risk if LDL-C is used alone in elderly, statin-treated women.
• Confounding factors such as age, smoking status, comorbidities, and therapy regimens may bias biomarker interpretation.

Patient & Prescribing Data

High-risk women, including elderly and postmenopausal patients, often on statin therapy

Statins reduce short-chain ceramide synthesis and alter phosphatidylcholine composition; omega-3 fatty acids and fibrates lower hepatic ceramide burden; hormone replacement therapy enhances anti-inflammatory lipid species, all influencing biomarker profiles and risk prediction.

Clinical Best Practices

• Incorporate female-specific risk factors and biomarkers into cardiovascular risk assessment algorithms.
• Use ApoB or non-HDL-C as robust lipid targets in women alongside LDL-C.
• Interpret ceramide-based risk scores cautiously in women due to sex differences and therapy modulation.
• Consider comprehensive lipid profiling including remnant cholesterol and ApoA-1 for improved risk stratification in women.
• Account for menopausal status, hormone therapy, and comorbidities when evaluating lipid biomarkers.

References

• Sex-specific disparities in lipid-based prediction of major cardiovascular events, Schnetzer et al.
• European Atherosclerosis Society Consensus on Women, Lipids, and ASCVD